On October 20, 2017, the U.S. Food and Drug Administration (FDA) licensed a new adjuvanted subunit vaccine containing varicella zoster virus glycoprotein E (HZ/su) for adults aged 50 years and older to prevent shingles. On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) voted that this vaccine is:
- recommended for healthy adults aged 50 years and older to prevent shingles and related complications
- recommended for adults who previously received the current shingles vaccine to prevent shingles and related complications
- the preferred vaccine for preventing shingles and related complications
This vaccine reduces the risk of developing shingles by 51% and PHN by 67% and is safer and more efficacious than the current live zoster vaccine.